Pharma Is Still Spending Billions on Keywords, Not Prescribers

Pharmaceutical marketers like to believe they are targeting healthcare professionals when they buy search ads against clinical keywords. But in most cases, they are targeting words, not prescribers.

For years, keyword targeting has served as a proxy for professional intent. The assumption: If someone searches for a drug name, a mechanism of action, or a condition-specific term, they must be a relevant clinician. That logic falls apart in healthcare, where patients, caregivers, students, and physicians routinely search for the same terms. The query tells you nothing about who is behind it or whether they have the authority to prescribe.

Still, billions of dollars in pharmaceutical marketing flow through this model every year.

How This Became the Default

Keyword-based targeting became standard because, for a long time, it was the only scalable option in sensitive healthcare categories. Audience-based approaches were limited in search environments. Measurement tools were built around clicks and site visits because those were the signals platforms exposed. The industry optimized toward what it could see, but what it could see was never the thing that mattered.

In healthcare, the commercial event is a prescribing decision. That decision is rarely impulsive. It unfolds over weeks or months. It is shaped by patient presentation, formulary status, peer consultation, and clinical judgment. It crosses multiple channels, and its timing depends on whether the right patient walks through the door. Keyword targeting was never designed for that complexity. It captures curiosity, not clinical authority or timing.

Compounding the problem is the fact that prescription data lives in entirely separate systems, governed by strict privacy requirements and complex compliance rules. Retail marketers can feed conversion data back into ad platforms and optimize toward revenue. In healthcare, bridging the gap between ad exposure and prescribing event requires identity resolution, technical rigor, and thoughtful scoping. Most of the industry defaulted to the simpler path of  measuring what is easiest.

The Quiet Cost

The result is a significant (largely invisible) inefficiency. When brands target “everyone who searched for X,” they are not isolating healthcare professionals. They are casting a wide net that includes large volumes of non-prescribers. Budgets intended for clinical influence function as broad consumer awareness spend.

Because keyword targeting lacks identity resolution tied to professional credentials, it is nearly impossible to know how much of that spend ever reached a verified prescriber. This creates a feedback loop. Marketers optimize toward available metrics of clicks, impressions, bounce rates. And those metrics gradually become the definition of success. The system rewards activity, not impact.

Meanwhile, the most valuable unit of analysis — incremental prescribing behavior — sits disconnected from the media plan.

From Proxies to Outcomes

The technical barriers that made keyword targeting the only viable option are eroding. Search platforms increasingly support sophisticated audience-based approaches. Claims data, electronic health records, and identity graphs have become more interoperable. The question is no longer whether we can move beyond keywords, it is why we haven’t.

Part of the answer is habit and part is comfort. Keyword targeting feels precise, looks intentional, and creates a sense of control. But healthcare marketing cannot afford to optimize for optics.

Consider the alternative: A campaign targeting verified endocrinologists, measured against a matched control group of comparable prescribers who were not exposed. Lift is calculated not on clicks, but on incremental new prescriptions written within an attribution window that reflects healthcare’s slower decision cycles of say, 90 days rather than the 7-day windows borrowed from retail. The media plan is informed by real-time signals tied to patient activity and prescribing behavior, not historical keyword volume. That is not a theoretical framework. The data infrastructure to support it exists today.

Building toward this model means accepting some uncomfortable truths. It means acknowledging that campaign dashboards showing strong click-through rates may be measuring the wrong thing entirely. It means restructuring measurement around a harder question: Did this campaign change clinical behavior in a measurable way?

Precision Should Mean Something

Keywords will remain part of the toolkit. But they should no longer be mistaken for precision targeting of prescribers. The next era of pharmaceutical marketing will belong to teams willing to move past what is easy to measure and build toward what actually matters, reaching the right clinician, at the right moment, and proving it made a difference